



ASX Announcement

04 March 2025

Cambium Bio Limited Announces Results of General Meeting

Sydney, Australia; 04 March 2025: Cambium Bio Limited (ASX:CMB) (**Cambium Bio, Cambium** or **Company**), a clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications, is pleased to announce that all resolutions put to shareholders at the General Meeting held today were passed.

Key Highlights:

- Approval to issue 3,989,650 Shares to Dr. Sebastian Tseng and Zheng Yang Biomedical Technology Co., Ltd (ZYBT) as part of the Part 3 Placement
- Approval to issue 120,000 Options and 50,000 Shares to Dr. Chandra Bala
- Approval to issue 50,000 Shares to Dr. Edmund Waller
- Approval to issue 50,000 Shares to Terence Walts

The details of the resolutions passed are as follows:

Resolution 1: Approval to issue Shares – Part 3 Placement – Sebastian Tseng and Zheng Yang Biomedical Technology Co., Ltd (ZYBT)

Resolution 1 was passed as an ordinary resolution with 98.83% of votes cast in favour.

This approval allows the Company to issue a total of 3,989,650 Shares to Sebastian Tseng and ZYBT (or their nominees), and acknowledges the increase in their relevant interests and voting power from 24.53% to up to 37.83% (in total).

Resolution 2: Approval of issue of Options and Shares under Part 3 Placement to Director – Dr. Chandra Bala

Resolution 2 was passed as an ordinary resolution with 99.42% of votes cast in favour.

This approval allows the Company to issue 120,000 Options and 50,000 Shares pursuant to the Part 3 Placement to Dr. Chandra Bala (or his nominee).

Resolution 3: Approval of issue of Shares under Part 3 Placement to Director – Edmund Waller

Resolution 3 was passed as an ordinary resolution with 99.38% of votes cast in favour.

This approval allows the Company to issue 50,000 Shares pursuant to the Part 3 Placement to Edmund Waller (or his nominee).

Resolution 4: Approval of issue of Shares under Part 3 Placement to Director – Terence Walts

Resolution 4 was passed as an ordinary resolution with 99.38% of votes cast in favour.

This approval allows the Company to issue 50,000 Shares pursuant to the Part 3 Placement to Terence Walts (or his nominee).

Karolis Rosickas, CEO of Cambium Bio, commented: "We are pleased with the strong support from our shareholders as demonstrated by the passing of all resolutions at today's General Meeting. The successful completion of the A\$3.0 million capital raising, including the Part 3 Placement approved today, provides us with the resources to advance our lead product candidate, Elate Ocular®, towards Phase 3 clinical trials. With the FDA Fast Track designation received in December 2024, FDA approval of our Phase 3 clinical trial protocol in February 2025, and the continued support of our strategic investors, we are well-positioned to progress our clinical development program and create value for our shareholders."

The Shares and Options approved at the General Meeting will be issued immediately following the meeting and in any event, no later than one month after the date of the meeting. Cambium Bio will receive A\$1.92 million in proceeds from the Part 3 Placement in the coming days, completing the A\$3.0 million capital raising announced in December 2024.

- ENDS -

About Cambium Bio Limited

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Cambium Bio Limited.

For further information, please contact:

Helen Leung
Corporate Secretary
info@cambium.bio
1 300 995 098



CAMBIUM BIO LIMITED

MUFG Corporate Markets
A Division of MUFG Pension & Market Services

GENERAL MEETING
Tuesday, 4 March, 2025

RESULT OF GENERAL MEETING (ASX REPORT)

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Total votes cast in the poll (where applicable)			
No	Short Description	Strike Y/N/NA	For	Against	Discretionary (open votes)	Abstain	For	Against	Abstain **	Result
1	APPROVAL TO ISSUE SHARES,PART 3 PLACEMENT,SEBASTIAN TSENG AND ZHENG YANG BIOMEDICAL TECHNOLOGY CO., LTD	NA	2,958,299 98.83%	12,004 0.40%	22,975 0.77%	113	2,995,774 99.60%	12,004 0.40%	113	Carried
2	APPROVAL OF ISSUE OF OPTIONS AND SHARES, UNDER PART 3 PLACEMENT, TO DIRECTOR DR CHANDRA BALA	NA	5,648,755 99.42%	11,004 0.19%	22,025 0.39%	113	5,685,280 99.81%	11,004 0.19%	113	Carried
3	APPROVAL TO ISSUE SHARES UNDER PART 3 PLACEMENT TO DIRECTOR EDMUND WALLER	NA	5,418,823 99.38%	12,004 0.22%	22,025 0.40%	113	5,455,348 99.78%	12,004 0.22%	113	Carried
4	APPROVAL TO ISSUE SHARES UNDER PART 3 PLACEMENT TO DIRECTOR TERENCE WALT	NA	5,474,850 99.38%	12,004 0.22%	22,025 0.40%	113	5,511,375 99.78%	12,004 0.22%	113	Carried

** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item